Trump  says Americans are ‘gaining tremendously’ from tariffs as he scrambles to combat criticism of the economy

President Trump is shifting his economic messaging to address growing voter concerns over affordability and inflation, following recent election results. His administration plans to emphasize new tax breaks, highlight drug price reductions (e.g., Eli Lilly, Novo Nordisk), and anticipate future Federal Reserve interest rate cuts to ease cost-of-living pressures. This strategic pivot occurs as consumer prices rose to 3% annually in September, with economic research indicating Trump's tariffs have contributed to inflation, a claim the administration disputes. The Supreme Court's ongoing review of the legality of these tariffs adds further uncertainty to future trade policy and its economic impact.

Analysis

President Trump is strategically re-centering his economic messaging on affordability and inflation, a pivot driven by recent election losses in states like New Jersey and Virginia where the economy was a primary voter concern. This shift includes plans to emphasize new tax breaks and highlight drug price reductions, such as those announced by Eli Lilly (LLY) and Novo Nordisk (NVO). The administration aims to counter the current consumer price increase, which reached an annual rate of 3% in September, up from 2.3% in April.

Underlying economic data presents a mixed picture and significant policy challenges. Economic research from Harvard and Northwestern suggests Trump's tariffs have contributed to inflation, estimating the rate would have been 2.2% without them, a claim the administration disputes. Concurrently, job gains have slowed by 23% year-over-year, and the Supreme Court is currently reviewing the legality of the administration's tariffs, introducing regulatory uncertainty.

Despite these headwinds, the White House anticipates a healthier economic environment within six months, projecting consistent cuts to the Federal Reserve's benchmark interest rate following Chair Powell's term end in May. This outlook, coupled with the administration's focus on consumer-level affordability initiatives like drug price negotiations and promoting retail deals (Walmart, Target), aims to improve public sentiment. However, the moderately negative sentiment and uncertain tone surrounding these developments suggest investor caution.

Key Decisions for Investors

• Monitor the Supreme Court's decision on tariff legality, as a ruling against the administration could alleviate inflationary pressures and impact import-reliant sectors.
• Assess the potential impact of anticipated Federal Reserve interest rate cuts on economic growth and specific sectors, particularly those sensitive to borrowing costs.
• Evaluate pharmaceutical companies like Eli Lilly (LLY) and Novo Nordisk (NVO) for potential revenue and margin compression due to increased government pressure on drug pricing.
• Observe consumer spending trends and retail sector performance (e.g., WMT, TGT) for signs of sustained affordability concerns or positive impacts from proposed tax breaks.